NewsBenzingaAcumen Pharmaceuticals wird auf der CTAD 2026 neue Phase-2-Daten der ALTITUDE-AD-Studie zu Sabirnetug bei früher Alzheimer-Krankheit vorstellen Acumen Pharmaceuticals wird auf der CTAD 2026 neue Phase-2-Daten der ALTITUDE-AD-Studie zu Sabirnetug bei früher Alzheimer-Krankheit vorstellen Benzinga 2026.10.22 11:36 (GMT+0) Open on Benzinga Other news RBC Capital Maintains Sector Perform on Thermo Fisher Scientific, Raises Price Target to $730 First Industrial Realty Q3 2026 Earnings Call Transcript Warren Buffett Who? Berkshire Stock Hits Records as These Holdings Drive Gains Under Greg Abel Texas Attorney General Ken Paxton Secures Settlement With Lululemon To Enforce Chemical Safety Standards And Protect Consumers From Harmful Chemicals In Activewear Meta’s $25 Billion Headache: The ETF Cashing In on META’s Pain Here's How Much $1000 Invested In CACI International 15 Years Ago Would Be Worth Today
Texas Attorney General Ken Paxton Secures Settlement With Lululemon To Enforce Chemical Safety Standards And Protect Consumers From Harmful Chemicals In Activewear
